2nd Quarter - Report — SOCIETY OF NUCLEAR MEDICINE AND MOLECUL… for SOCIETY OF NUCLEAR MEDICINE AND MOLECUL… (2015)

Firm

SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Client

SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Income

—

Expenses

$90,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Implementation of the radiopharmaceutical provisions of The Drug Quality and Security Act as it relates to compounding.

Lobbyist	Covered position, as disclosed
SUSAN KATHLEEN BUNNING	—
CAITLIN BLAKE KUBLER	—

Contacted: Nuclear Regulatory Commission (NRC); Office of Science & Technology Policy (OSTP); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Drug Enforcement Administration (DEA); Centers For Medicare and Medicaid Services (CMS); SENATE; Energy, Dept of

Budget/Appropriations BUD

Energy/Water and Labor/HHS/Education appropriations generally for DOE and NIH funding opportunities for nuclear medicine.

Lobbyist	Covered position, as disclosed
SUSAN KATHLEEN BUNNING	—
CAITLIN BLAKE KUBLER	—

Contacted: SENATE; Food & Drug Administration (FDA); Drug Enforcement Administration (DEA); Nuclear Regulatory Commission (NRC); HOUSE OF REPRESENTATIVES; Office of Science & Technology Policy (OSTP); Centers For Medicare and Medicaid Services (CMS); Energy, Dept of

Energy/Nuclear ENG

Domestic isotope supply issues generally, including oversight of the American Medical Isotope Production Act of 2011. Medical radiation issues generally, including Nuclear Regulatory Commission regulations.

Lobbyist	Covered position, as disclosed
SUSAN KATHLEEN BUNNING	—
JESSE SCHOOLNIK	—

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Office of Science & Technology Policy (OSTP); Energy, Dept of; Nuclear Regulatory Commission (NRC); Centers For Medicare and Medicaid Services (CMS); Drug Enforcement Administration (DEA); SENATE

Law Enforcement/Crime/Criminal Justice LAW

Issues relating to a controlled substance nuclear medicine drug.

Lobbyist	Covered position, as disclosed
SUSAN KATHLEEN BUNNING	—

Contacted: Nuclear Regulatory Commission (NRC); Drug Enforcement Administration (DEA); HOUSE OF REPRESENTATIVES; Office of Science & Technology Policy (OSTP); SENATE; Energy, Dept of; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA)

Health Issues HCR

21st Century Cures initiative generally; and the creation of a new imaging drug approval pathway at the FDA specifically.

Lobbyist	Covered position, as disclosed
SUSAN KATHLEEN BUNNING	—
CAITLIN BLAKE KUBLER	—

Contacted: Food & Drug Administration (FDA); Office of Science & Technology Policy (OSTP); SENATE; Nuclear Regulatory Commission (NRC); HOUSE OF REPRESENTATIVES; Drug Enforcement Administration (DEA); Energy, Dept of; Centers For Medicare and Medicaid Services (CMS)

Medicare/Medicaid MMM

Nuclear medicine reimbursement generally and nuclear medicine APC's under HOPPS and appropriate use criteria under the MPFS specifically. Sustainable growth rate provisions of H.R. 2, the "Medicare Access and CHIP Reauthorization Act of 2015."

Lobbyist	Covered position, as disclosed
SUSAN KATHLEEN BUNNING	—
JESSE SCHOOLNIK	—

Contacted: HOUSE OF REPRESENTATIVES; Office of Science & Technology Policy (OSTP); Drug Enforcement Administration (DEA); Energy, Dept of; SENATE; Nuclear Regulatory Commission (NRC); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA)

Bills named: H.R. 2 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.